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Our previous study indicated that 071031B, a novel potential serotonin and norepinephrine reuptake
inhibitor, showed robust antidepressant activity in multiple depression models, and could simulta-
neously inhibit 5-HT and NE reuptake in vitro. The present study was to evaluate the effects of 071031B
on monoamine system in vivo, by using pharmacological models, including 5-HTP induced head-twitch
test, yohimbine toxicity potentiation test, and reserpine induced hypothermia test, and determining
monoamine transmitter levels in reserpine induced monoamine depletion model or chronic unpre-
dictable stress (CUS) model. Results in pharmacological models indicated that acute administration of
071031B at 5e20 mg/kg signiﬁcantly enhanced 5-HTP induced head-twitch behavior, potentiated
yohimbine induced lethal rate, and reversed reserpine induced hypothermia. Further monoamine assays
demonstrated that acute or chronic administration of 071031B at 10 or 20 mg/kg increased 5-HT and/or
NE levels in various brain regions in reserpine or CUS induced monoamine depletion models, respec-
tively, without effect on DA and its metabolites. Our results revealed that 071031B produces potent in-
hibition of 5-HT and NE reuptake in vivo.
© 2015 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Depression is a complicated psychiatric disorder with various
types of symptoms, which suggest that depression is induced by
complicated interaction within multiple factors and systems.
Within various etiology hypotheses, monoamine hypothesis sup-
ports that low levels of monoamines, especially serotonin (5-HT)
and norepinephrine (NE), contribute to the occurrence of depres-
sion (1). Drug induced enforcement on monoamine system is
beneﬁcial in depression therapy, and can be realized by three
strategies, inhibiting monoamine reuptake, e.g., ﬂuoxetine, rebox-
etine, or duloxetine targeting at monoamine transporters, orvaluation, Beijing Institute of
g 100850, PR China. Tel.: þ86
valuation, Beijing Institute of
g 100850, PR China. Tel.: þ86
. Zhong), 13901363887@163.
rmacological Society.
r B.V. on behalf of Japanese Pharminhibiting monoamine metabolism, e.g., moclobemide targeting at
monoamine oxidase A, or increasing monoamine release indirectly,
e.g., agomelatine, marketed as the ﬁrst antidepressant beyond
monoaminergic targets, exerts antidepressant effects partially
depending on its antagonistic activity at 5-HT2C receptors and
subsequent outﬂows of NE and dopamine (DA) (2). 5-HT and NE are
the most crucial transmitters in depression etiology and therapy,
albeit their effects were not the same. 5-HT enhancement was
closely related with emotion improvement, while NE was reported
to show positive effect on motivation or anhedonia (3). These may
partially support that dual reuptake inhibitors show better efﬁcacy
than the single ones (4).
Our previous studies indicated that a novel serotonin and
norepinephrine reuptake inhibitor (SNRIs) 071031B ((±)-3-(benzo
[d] [1,3]dioxol-4-yloxy)-N-methyl-3-(thiophen-2-yl) propan-1-
amine, Fig. 1) showed robust antidepressant activity in multiple
depression models, i.e., tail suspension test in mice, forced swim-
ming test in mice and rats, and chronic unpredictable stress model
in rats (5, 6). Target research indicated that 071031B could bind to
5-HT transporter (SERT) and NE transporter (NET) simultaneously
and then inhibit these two transmitters' reuptake in vitro, whichacological Society. This is an open access article under the CC BY-NC-ND license
Fig. 1. Chemical structure of 071031B.
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However, it should be noted that in vitro data from binding or
uptake may not mimic and then represent true process in vivo. We
all know that neuron discharge and neurotransmitter release is
mediated by auto receptors, i.e., increase of 5-HT or NE would
activate 5-HT1A or a2 auto receptors and this activation would in
turn suppress neuron discharge and then reduce transmitter
release, and the further reciprocal interactions between 5-HT and
NE systems make the actual process of neurotransmitter release
more complicated (7). What are the ﬁnal results following these
interactions? Accordingly, in vivo process is more complicated that
can not be speculated by in vitro data. The present study was to
systematically evaluate the effects of 071031B on monoamine
system in vivo, by using pharmacological models, including 5-HTP
induced head-twitch test, yohimbine toxicity potentiation test, and
reserpine induced hypothermia test, and determining monoamine
transmitter levels in reserpine induced monoamine depletion
model or chronic unpredictable stress model.2. Materials and methods
2.1. Animals
Unless speciﬁed below, male ICR mice weighing 18e20 g and
male SpragueeDawley rats weighing 180e200 g were used (Bei-
jing Vital River Laboratory Animal Technology Company, Beijing,
China). Animals were group housed under standard condition as
previously described (5). Experiments were approved by the local
Animal Welfare Committee for Animal Experiments at Beijing
Institute of Pharmacology and Toxicology, and were performed in
compliance with Guiding Principles for the Care and Use of Lab-
oratory Animals approved by the Japanese Pharmacological
Society.2.2. Materials
Duloxetine hydrochloride was purchased from Beijing Fur-
enkang Biopharmaceutical Corporation, Ltd (Beijing, China).
071031B oxalate was synthesized at Beijing Institute of Pharma-
cology and Toxicology. Fluoxetine, 5-hydroxy-L-tryptophan (5-
HTP), yohimbine hydrochloride, reserpine hydrochloride, 5-HT,
DA, NE, 5-hydroxyindole-3-acetic acid (5-HIAA), homovanillic acid
(HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were pur-
chased from Sigma Aldrich (St. Louis, MO, USA). Vehicle or drugs
were dissolved in distilled water and administered orally (p.o.),
intraperitoneally (i.p.), or subcutaneously (s.c.) in a volume of
10 ml/kg for mice and 2 ml/kg for rats.2.3. 5-HTP induced head-twitch test in mice
The test was performed as previously described (8, 9). Sixty
minutes after acute p.o. administration of vehicle, duloxetine, or
various doses of 071031B, 5-HTP (120mg/kg) were injected i.p., and
then the number of head-twitches (rapid movements of the head
with little or no involvement of the trunk) was counted immedi-
ately for 20 min.
2.4. Yohimbine toxicity potentiation test in mice
The procedure was performed as previously described (9, 10).
Sixty minutes after acute p.o. administration of vehicle, duloxetine,
or 071031B at various doses, yohimbine (30mg/kg) was injected s.c.,
and then the number of death was recorded in the following 24 h.
2.5. Reserpine induced hypothermia test in rats
The test was performed as previously described with minor
modiﬁcations (11). Reserpine (5mg/kg) was injected i.p. 17 h before
drug treatment. Seventeen hours later, rectal temperature was
recorded as basal temperature (t0, C), and then, vehicle, dulox-
etine, and 071031B at various doses were administered i.p. imme-
diately. Sixty minutes after drug treatment, rectal temperature was
measured again (t1, C). The difference (△T, C) between t0 and t1
was calculated. After temperature assays, various regions of rat
brain were isolated to assess the effects of reserpine and 071031B
on levels of monoamines and their metabolites using high perfor-
mance liquid chromatography with electrochemical detection
(HPLC-ECD).
2.6. Chronic unpredictable stress procedure
The chronic unpredictable stress procedure was developed as
previously described (5). Rats were divided into six groups: Control
(non-stress), Stress-Vehicle (distilled water), Stress-Fluoxetine
(10 mg/kg), Stress-Duloxetine (10 mg/kg), Stress-071031B (5 or
10 mg/kg). Drugs were administered orally once daily for 4 weeks.
Except for control group, rats were subjected to a variety of stressors
described in Fig. 2 and Table 1 and 4 weeks later, the open-ﬁeld test,
the sucrose preference test, and the novelty-suppressed feeding test
were performed. The behavioral results of 071031B in CUS model
have been reported in our previous research (5), and brains from the
same rats were used to assess the effects of stress and 071031B on
levels of monoamines and their metabolites using HPLC-ECD.
2.7. Monoamine assays by HPLC-ECD
Measurements of monoamine transmitters (5-HT, NE, DA) and
their metabolites (5-HIAA, DOPAC, HVA) in various brain regions
were performed using HPLC-ECD as previously described (9).
Brieﬂy, tissue samples were homogenized in 0.4 N perchloric acid
with 0.5 mM Na2-EDTA and 0.01% L-cysteine (5 or 10 ml/mg of
tissue), and were centrifuged for 30 min at speed of 12,000 rpm at
4 C. The supernatant were collected and analyzed. The HPLC
system, the mobile phase consistence and other speciﬁc details
were referred to the protocol established by our team (9). Sample
levels of monoamines and related metabolites were quantiﬁed
according to standard curve, taking area under curve (AUC) as an
index.
2.8. Statistical analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Prism5.0, version 2.0; GraphPad Software Inc., San Diego,
Fig. 2. Chronic unpredictable stress (CUS) regime.
Table 1
Chronic unpredictable stress regime.
Day Week
Week 1 Week 2 Week 3 Week 4
Sunday White noise: 1 h
Overnight stroboscope: 12 h
Cage tilt: 24 h Cage tilt: 24 h Cage tilt: 24 h
Monday Food deprivation: 24 h Shock: 30 min Shock: 30 min Forced swimming: 5 min
Tuesday Restraint: 1 h
Overnight illumination: 12 h
White noise: 2 h
Overnight illumination: 12 h
Water deprivation: 24 h Soiled cage: 24 h
Wednesday Tail pinch: 1 min Restraint: 2 h
Overnight stroboscope: 12 h
Tail pinch: 1 min Shock: 30 min
Thursday Soiled cage: 24 h Soiled cage: 24 h Soiled cage: 24 h Tail pinch: 1 min
Friday Forced swimming: 5 min Forced swimming: 5 min Restraint: 2 h
Overnight stroboscope: 12 h
Food deprivation: 24 h
Saturday Water deprivation: 24 h Food deprivation: 24 h Water deprivation: 24 h Cage tilt: 24 h
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t-test or one-way analysis of variance (ANOVA) followed by Dun-
nett's test. For data that exhibiting unequal variances, Man-
neWhitney U test or KruskaleWalis test followed by Dunn's
Multiple ComparisonTestwas applied. Data formyohimbine toxicity
potentiation test in mice were analyzed using Fisher's exact test.3. Results
3.1. Effects of 071031B on 5-HTP induced head-twitch behavior
Fig. 3 shows that co-administration of 071031B (5, 10, or 20 mg/
kg, p.o.) and 5-HTP elicited a pronounced head-twitch behavior in
mice in a dose-dependent manner (one-way ANOVA,Fig. 3. Effects of 071031B (5e20 mg/kg) or duloxetine (20 mg/kg) on 5-HTP induced
head-twitch behavior in mice. Vehicle (VEH), duloxetine (DLX), or 071031B was
administered p.o. 60 min prior to 5-HTP (120 mg/kg, i.p.) injection. Data are presented
as means ± S.E.M. (n ¼ 10/group). *p < 0.05, **p < 0.01 vs. VEH.F4,45 ¼ 4.281; p ¼ 0.0051). Further post-hoc analysis revealed that
071031B (p.o.) at the doses of 10 and 20 mg/kg signiﬁcantly
increased the number of head-twitches (Dunnett's test, as
comparedwith vehicle, p< 0.05 for 10mg/kg, p< 0.01 for 20mg/kg,
respectively). Similar effect was produced by duloxetine at 20 mg/
kg (Dunnett's test, p < 0.05).
3.2. Effects of 071031B on yohimbine induced lethal toxicity
As shown in Table 2, yohimbine injection only induced 10%
mortality rate, while combined administration of 071031B at doses
of 5e20 mg/kg signiﬁcantly increased the mortality rates to 100%,
90% or 100%, respectively (Fisher's exact test, as compared with
vehicle, p¼ 0.0001 for 5 mg/kg, p¼ 0.0011 for 10mg/kg, p¼ 0.0001
for 20 mg/kg, respectively). Similar effect was produced by dulox-
etine at 20 mg/kg (p ¼ 0.0001).
3.3. Effects of 071031B on reserpine induced hypothermia response
Intraperitoneal injection of reserpine at 5 mg/kg induced obvi-
ously hypothermia response. As shown in Fig. 4, 071031B at
5e20 mg/kg signiﬁcantly reduced reserpine induced hypothermia,
as evidenced by the decreased △T/(C) values (one-way ANOVA,
F4,43 ¼ 7.600, p ¼ 0.0001; Dunnett's test was chose as post-hoc
test, as compared with VEH, p < 0.001 for 5 mg/kg, p < 0.001 forTable 2
Effects of 071031B on the mortality rate in the yohimbine toxicity potentiation test
in mice.
Group Dose/(mg/kg) Number of death in 24 h Mortality rate in 24 h/(%)
Vehicle e 1 10
DLX 20 10 100***
071031B 5 10 100***
10 9 90***
20 10 100***
***P < 0.001 versus vehicle, Fisher's exact test. n ¼ 10.
Fig. 4. Effects of 071031B (5e20 mg/kg) or duloxetine (20 mg/kg) on reserpine-
induced hypothermia in rats. Reserpine (5 mg/kg) was injected i.p. 17 h before
vehicle (VEH), duloxetine (DLX), or 071031B treatment, and rectal temperature was
measured sixty minutes after drug treatment. Data are presented as means ± S.E.M.
(n ¼ 10/group). **p < 0.01, ***p < 0.001 vs. VEH.
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at 20 mg/kg administered 1 h before test did not produce antago-
nizing effect on body temperature in resperpinized rats (Dunnett's
test, p > 0.05).3.4. Effects of 071031B on reserpine induced monoamine changes
Table 3 illustrates the effects of 071031B or duloxetine on the
levels of monoamine and metabolites in prefrontal cortex, hippo-
campus, hypothalamus and striatum in reserpinized rats. As
compared with vehicle (reserpine ()), pretreatment of reserpine
at 5 mg/kg signiﬁcantly decreased levels of 5-HT and NE, and
increased levels of 5-HIAA/5-HT, in prefrontal cortex (as for 5-HT,
Mann Whitney test, U ¼ 0.0000, p ¼ 0.0025; as for NE, Student's t-
test, t ¼ 9.444, p < 0.0001; as for 5-HIAA/5-HT, MannWhitney test,
U ¼ 0.0000, p < 0.01), hippocampus (as for 5-HT, Student's t-test,
t ¼ 4.713, p ¼ 0.0006; as for NE, Student's t-test, t ¼ 4.678,Table 3
Effects of 071031B on levels of monoamines and related metabolites (ng/mg) in prefront
Groups Reserpine () Reserpine þ VEH Reserpine þ D
20 (mg/kg)
Prefrontal cotex
5-HT 0.475 ± 0.111 0.021 ± 0.007** 0.070 ± 0.07
5-HIAA 0.395 ± 0.071 0.628 ± 0.059*** 0.402 ± 0.15
5-HIAA/5-HT 0.856 ± 0.166 33.630 ± 12.180** 7.537 ± 4.72
NE 0.570 ± 0.085 0.157 ± 0.060*** 0.297 ± 0.08
Hippocampus
5-HT 0.492 ± 0.171 0.088 ± 0.138*** 0.065 ± 0.05
5-HIAA 0.659 ± 0.165 1.012 ± 0.268* 0.558 ± 0.12
5-HIAA/5-HT 1.430 ± 0.397 342.800 ± 558.100** 15.240 ± 16.0
NE 0.596 ± 0.097 0.257 ± 0.155*** 0.219 ± 0.10
Hypothalamus
5-HT 0.536 ± 0.091 0.034 ± 0.012** 0.162 ± 0.05
5-HIAA 0.536 ± 0.094 0.812 ± 0.258* 0.634 ± 0.30
5-HIAA/5-HT 1.020 ± 0.239 27.510 ± 7.004** 4.359 ± 2.45
NE 10.783 ± 2.091 0.161 ± 0.061** 0.427 ± 0.22
Striatum
DA 7.400 ± 0.660 0.284 ± 0.490*** 0.438 ± 0.16
DOPAC 2.702 ± 0.335 0.837 ± 0.211*** 1.022 ± 0.28
HVA 0.647 ± 0.114 0.484 ± 0.202 0.663 ± 0.34
Values are expressed as means ± S.D. (n ¼ 5e10). *P < 0.05, **P < 0.01, ***P < 0.001 ver
###P < 0.001 versus Reserpine þ VEH, ANOVA followed by Dunnett's test or KruskaleWp ¼ 0.0005; as for 5-HIAA/5-HT, Mann Whitney test, U ¼ 0.0000,
p ¼ 0.0022) and hypothalamus (as for 5-HT, Mann Whitney test,
U ¼ 0.0000, p ¼ 0.0016; as for NE, Mann Whitney test, U ¼ 0.0000,
p ¼ 0.0025; as for 5-HIAA/5-HT, Mann Whitney test, U ¼ 0.0000,
p < 0.01); reserpine also decreased DA (Student's t-test, t ¼ 23.51,
p < 0.0001) and increased DOPAC levels (Student's t-test, t ¼ 13.79,
p < 0.0001) in striatum.
In prefrontal cortex, 071031B showed increasing effects on
levels of 5-HT (KruskaleWalis test, KruskaleWalis statistic
4,36 ¼ 21.13, p ¼ 0.0003) or NE (one-way ANOVA, F4,38 ¼ 2.264,
p ¼ 0.0802) and decreasing effects on those of 5-HIAA/5-HT
(KruskaleWalis test, KruskaleWalis statistic 4,36 ¼ 25.32,
p < 0.0001), and post-hoc analysis revealed that, as compared with
reserpine group, it was signiﬁcant at the dose of 20 mg/kg for 5-HT
(Dunn's Multiple Comparison Test, p < 0.001), 10 mg/kg for NE
(Dunnett's test, p < 0.05) and 20 mg/kg for 5-HIAA/5-HT (Dunn's
Multiple Comparison Test, p < 0.001). Duloxetine at 20 mg/kg
showed no effect on 5-HT (p > 0.05), increasing effect on NE
(p < 0.05), and decreasing effect on 5-HIAA/5-HT (p < 0.05) levels.
In hippocampus, 071031B or duloxetine showed no effect on
levels of 5-HT (KruskaleWalis test, KruskaleWalis statistic
4,36 ¼ 4.555, p ¼ 0.336) and NE (KruskaleWalis test, Krus-
kaleWalis statistic 4,40 ¼ 0.7670, p ¼ 0.9428), while reserpine
induced 5-HIAA/5-HT enhancement was antagonized by 071031B
at 5e20 mg/kg and duloxetine at 20 mg/kg (one-way ANOVA fol-
lowed, F4,33 ¼ 2.650, p ¼ 0.0506; Dunnett's test, p < 0.05 for
071031B at all doses and duloxetine at 20 mg/kg, respectively).
In hypothalamus, 071031B showed increasing effects on levels
of 5-HT (KruskaleWalis test, KruskaleWalis statistic 4,36 ¼ 23.71,
p < 0.0001) and NE (KruskaleWalis test, KruskaleWalis statistic
4,36 ¼ 14.69, p ¼ 0.0054) and decreasing effects on those of 5-
HIAA/5-HT (KruskaleWalis test, KruskaleWalis statistic
4,35 ¼ 24.27, p < 0.0001). Post-hoc analysis revealed that, as
compared with reserpine group, 071031B at 20 mg/kg signiﬁcantly
enhanced both 5-HT and NE levels and decreased 5-HIAA/5-HT
values (Dunn's Multiple Comparison Test, p < 0.01, p < 0.05,
p < 0.01, respectively), 071031B at 10 mg/kg decreased 5-HIAA/5-
HT values (Dunn's Multiple Comparison Test, p < 0.05), and
071031B at 5 mg/kg showed no effect on these three measure-
ments. Duloxetine at 20mg/kg showed similar increasing effects on
5-HT and NE levels and decreasing effects on 5-HIAA/5-HT valuesal cortex, hippocampus, striatum and hypothalamus in reserpinized rats.
LX Reserpine þ 071031B
5(mg/kg) 10 (mg/kg) 20 (mg/kg)
7 0.035 ± 0.035 0.058 ± 0.088 0.141 ± 0.047###
0## 0.497 ± 0.124 0.442 ± 0.136# 0.437 ± 0.128#
9# 22.790 ± 12.35 17.790 ± 16.08 3.300 ± 1.149###
1# 0.245 ± 0.129 0.296 ± 0.122# 0.241 ± 0.070
3 0.033 ± 0.025 0.077 ± 0.123 0.110 ± 0.120
2### 0.860 ± 0.290 0.742 ± 0.157# 0.685 ± 0.121#
10# 40.820 ± 28.100# 31.760 ± 21.700# 19.660 ± 17.910#
5 0.221 ± 0.088 0.299 ± 0.182 0.210 ± 0.044
2### 0.077 ± 0.036 0.072 ± 0.035 0.131 ± 0.069##
0 0.746 ± 0.282 0.448 ± 0.091## 0.642 ± 0.216
4### 13.280 ± 9.599 7.016 ± 4.391# 5.867 ± 2.926##
6## 0.287 ± 0.101 0.246 ± 0.057 0.437 ± 0.290#
0 0.303 ± 0.136 0.268 ± 0.143 0.355 ± 0.330
9 0.908 ± 0.177 0.844 ± 0.220 0.798 ± 0.158
3 0.720 ± 0.464 0.566 ± 0.238 0.544 ± 0.210
sus Reserpine (), Student's t-test or ManneWhitney U test; #P < 0.05, ##P < 0.01,
alis test followed by Dunn's Multiple Comparison Test.
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In striatum, both 071031B and duloxetine showed no effect on
levels of DA (one-way ANOVA, F4,34 ¼ 2.264, p ¼ 0.6987), DOPAC
(one-way ANOVA, F4,42 ¼ 1.449, p ¼ 0.2350), or HVA (one-way
ANOVA, F4,42 ¼ 0.9171, p ¼ 0.4630).3.5. Effects of 071031B on CUS induced monoamine changes
Table 4 illustrates the effects of 071031B or duloxetine on levels
of monoamine and metabolites in prefrontal cortex and striatum in
CUS rats.
In prefrontal cortex, as compared with vehicle (stress ()), four-
week stress induced pronounced decreasing in levels of NE (Stu-
dent's t-test, t¼ 2.761, p¼ 0.0162), while levels of 5-HT (Student's t-
test, t ¼ 0.4675, p ¼ 0.6473) or 5-HIAA (Student's t-test, t ¼ 0.9219,
p ¼ 0.3722) showed no change. As compared with stress group,
071031B, ﬂuoxetine, or duloxetine showed increasing effects on
levels of NE (one-way ANOVA, F4,30 ¼ 3.438, p ¼ 0.0209) and 5-HT
(one-way ANOVA, F4,30 ¼ 0.2968, p ¼ 0.0277), decreasing effects
on those of 5-HIAA (one-way ANOVA, F4,30 ¼ 10.11, p < 0.0001).
Post-hoc analysis revealed that 071031B at 10 mg/kg, duloxetine at
10 mg/kg, or ﬂuoxetine at 10 mg/kg, could signiﬁcantly increase
levels of NE in CUS rats (Dunnett's test, p < 0.05, p < 0.05, p < 0.05,
respectively), without effect on that 5-HT (Dunnett's test, p > 0.05,
p > 0.05, p > 0.05, respectively). Fluoxetine at 10 mg/kg also
decreased 5-HIAA levels (Dunnett's test, p < 0.001) in CUS rats.
In striatum, as compared with vehicle (stress ()), four-week
stress showed no effect on levels of DA, DOPAC, or HVA (Student's
t-test; for DA, t ¼ 0.6652, p ¼ 0.5185; for DOPAC, t ¼ 0.4723,
p ¼ 0.6452; for HVA, t ¼ 0.880, p ¼ 0.3948). As compared with
stress group, 071031B, ﬂuoxetine, or duloxetine showed no effect
on levels of DA, DOPAC, or HVA (one-way ANOVA; for DA,
F4,28 ¼ 0.6052, p ¼ 0.6622; for DOPAC, F4,28 ¼ 0.3972, p ¼ 0.8089;
for HVA, F4,28 ¼ 2.035, p ¼ 0.1166).4. Discussion
The inhibition of reuptake of 5-HT/NE in vitro, and the
enhancing of serotonergic and noradrenergic transmission in vivo
are characteristics of SNRIs. Our previous study have demonstrated
that 071031B is an inhibitor of both 5-HT and NE transporters, and
inhibits these two transmitters reuptake in brain in vitro (5). The
present study demonstrated that 071031B produced serotonergic
and noradrenergic neuronal activation in vivo, for it could signiﬁ-
cantly increase 5-HTP induced head etwitch number, potentiate
toxicity caused by yohimbine and reverse hypothermia induced by
reserpine, and most importantly, 071031B could block the deple-
tion of 5-HT and/or NE induced by reserpine or chronic stress.Table 4
Effects of 071031B on levels of monoamines and related metabolites (ng/mg) in prefront
Groups Stress () Stress þ VEH Stress þ FLX
Prefrontal cotex
5-HT 0.956 ± 0.128 0.929 ± 0.108 0.846 ± 0.08
5-HIAA 0.883 ± 0.162 0.817 ± 0.121 0.541 ± 0.15
5-HIAA/5-HT 0.948 ± 0.253 0.901 ± 0.225 0.643 ± 0.18
NE 0.808 ± 0.119 0.682 ± 0.062* 0.818 ± 0.18
Striatum
DA 17.206 ± 5.292 19.361 ± 6.458 18.563 ± 6.21
DOPAC 3.799 ± 1.666 4.287 ± 2.076 3.665 ± 0.88
HVA 1.008 ± 0.199 0.906 ± 0.244 0.816 ± 0.22
Values are expressed as means ± S.D. (n ¼ 5e8). *P < 0.05 versus Stress (),Student's t-teAdditional injection of 5-HTP, the precursor of 5-HT, increases
5-HT levels abruptly in brain, and antidepressants, that exert
potential activating effect on serotonergic system, will further
enhance 5-HT concentration and then induce rapid head-twitch
movement by activating 5-HT2A receptor (8). Our results indi-
cated that combination of 071031B and 5-HTP induced obvious
head-twitch behavior, indicating that 071031B enhanced seroto-
nergic system function in vivo. Duloxetine at 20 mg/kg showed
similar effect, which was in accordance with the ﬁndings of Katoh
et al. (12).
Yohimbine at ultra dose, by antagonizing alpha2 receptor and
then increasing central NE concentration sharply, will lead to the
death of mice (10). Co-administration of antidepressants, who have
potential activating role in central noradrenergic system, will
potentiate toxicity of yohimbine. In the current study, we demon-
strated that co-administration of 071031B at 5e20 mg/kg and
yohimbine caused almost 100% mortality, suggesting 071031B
activated central noradrenergic system in vivo.
Reserpine could induce hypothermia action in animals or
human by depleting NE levels, and antidepressants that have
potential activating role in central noradrenergic system will
inhibit or reverse this response. The present study demonstrated
that 071031B at 5e20 mg/kg effectively reversed reserpine
induced hypothermia, suggesting 071031B activated central
noradrenergic system in vivo, yet this action showed a biphasic
U-shape curve, i.e., the inhibition effect of 071031B at higher dose
(20 mg/kg) was weaker than that at lower doses (5 or 10 mg/kg).
In fact, Katoh et al (12) found that duloxetine showed similar
characteristics, and their explanation was that high doses (25 and
50 mg/kg) of duloxetine may affect body temperature directly.
Furthermore, in our study, duloxetine at 20 mg/kg could not
signiﬁcantly reduce reserpine induced hypothermia, which
seemed to be inconsistent with previous study by Katoh et al.
However, it should be noted that, studies from Katoh's lab and
ours' used totally different experiment procedures. Firstly, rats
were used in our study while mice were used in Katoh's study;
secondly, the dose of reserpine was 5 mg/kg and 1 mg/kg in our
and Katoh's study, respectively; then, in our study, we ﬁrst
injected reserpine and 17 h later, we gave duloxetine, then 1 h
later, we tested mice's body temperature; whereas in Katoh's
study, reserpine was injected 1hr after the administration of
duloxetine, and the temperature was measured at various time
points, yet not more than 5hr. Moreover, pharmacokinetic prop-
erties may also be a crucial factor contributing to duloxetine's
invalid effect in the current study, for we only tested body tem-
perature at one time point, i.e., 18 h. Results from pharmacolog-
ical models demonstrated that 071031B could activate both 5-HT
and NE system in vivo. Subsequently, we want to ensure whether
this activation was realized by increasing 5-HT and NE trans-
mitter's concentration.al cortex and striatum in CUS rats.
Stress þ DLX Stress þ 071031B
10 (mg/kg) 5 (mg/kg) 10 (mg/kg)
5 1.039 ± 0.162 0.988 ± 0.131 1.041 ± 0.116
3### 0.867 ± 0.099 0.944 ± 0.126 0.758 ± 0.129
6# 0.842 ± 0.099 0.958 ± 0.086 0.732 ± 0.130
7# 0.863 ± 0.118# 0.823 ± 0.122 0.878 ± 0.110#
4 21.225 ± 3.124 21.976 ± 4.840 22.124 ± 3.753
9 3.627 ± 1.504 4.790 ± 2.094 4.153 ± 2.650
6 1.015 ± 0.181 1.129 ± 0.267 0.933 ± 0.139
st; #P < 0.05, ###P < 0.001 versus Stress þ VEH, ANOVA followed by Dunnett's test.
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involve a complicated process. Accordingly, in the present study,
we assessed 071031B's effect on monoamine levels and focused on
the changes under depressive state. Although reserpine was an
antihypertensive drug, clinical research in 1970's found that
reserpine treatment would lead to depression by depleting
monoamine levels. Indeed, our results in HPLC analyses revealed
that pretreatment with reserpine at 5 mg/kg induced signiﬁcant
decreases in three monoamine transmitters, i.e., 5-HT, NE, DA, and
increases in values of 5-HIAA/5-HT and DOPAC/DA in various brain
regions. 071031B or duloxetine reduced 5-HT turnover in all three
regions of reserpinized rats, while their increasing effects on 5-HT
or NE levels were brain-region speciﬁc. Only in hypothalamus did
071031B or duloxetine increase 5-HT and NE levels simultaneously,
whereas no effects were observed in hippocampus. In prefrontal
cortex, only one type of transmitters was increased by duloxetine at
20 mg/kg or 071031B at 10 and 20 mg/kg. However, although there
was no statistical signiﬁcance, the other type of transmitters was
also increased by more than 50% following duloxetine or 071031B
treatment. Frontal cortex is of particular interest for SNRIs research
because of its extensive serotonergic and noradrenergic in-
nervations and interactions (13). Actually, we found that the po-
tency of 071031B to NE uptake inhibition was greater in frontal
cortex than hippocampus (data not shown). Gehlert et al (14) found
similar brain region difference, and they reported that the potency
to inhibit NE uptake by duloxetine was greater in hypothalamus.
Like frontal cortex, hypothalamus also received extensive seroto-
nergic and noradrenergic innervations. The mechanisms of this
brain-speciﬁc response were not clear, yet may be related to two
reasons. First, density of serotonergic and noradrenergic nerve ﬁber
varies between brain areas, and interactions between 5-HT and NE
differ too. Second, different drugs may have different characteris-
tics, including pharmacodynamic and pharmacokinetic proﬁles.
Muneoka et al (15) also demonstrated that SNRIs induced changes
in monoamines were brain-region speciﬁc. Both 071031B and
duloxetine showed no effect on DA or its turn over in striatum.
Chronic unpredictable stress (CUS) model is themost commonly
used animal model in researching depression, for it induces similar
behavioral deﬁcits and neurochemical disturbances as depressive
patients (16). The antidepressant effects of 071031B in CUS model
were described previously (5), and using same animals, our current
study demonstrated that 071031B was effective on CUS induced NE
depletion. HPLC analyses revealed that a four-week stress regime
presented in Table 1 induced signiﬁcant reduction in NE level in
prefrontal cortex, without inﬂuencing 5-HT level and its turnover in
prefrontal cortex or DA and its turnover in striatum. Rats treated
with 071031B or duloxetine produced signiﬁcant increases in NE
levels in prefrontal cortex. Interestingly, it is worth noting that
ﬂuoxetine, as a selective serotonin reuptake inhibitor, restored NE
level in prefrontal cortex in CUS rats to the same extent as dulox-
etine or 071031B. In fact, Bymaster et al. (17) have shown that
ﬂuoxetine, but not other SSRIs, increases NE and DA extracellular
levels in prefrontal cortex without effects on blocking NET at the
same dose, which is proposed to be due to ﬂuoxetine's blocking
effects on 5-HT2C receptors. To our knowledge, our study reported
the increasing effects of ﬂuoxetine on NE levels in CUS model for
the ﬁrst time. Numerous studies reported relatively consistent
behavioral endpoints in CUS model, while neurochemical end-
points varied between (or indeed, within) laboratories. For
instance, Harro et al found that 2w variable stress only induced
HVA increasing in prefrontal cortex, without affecting 5-HT and NE
levels in prefrontal cortex or hippocampus (18), whereas Bhutani
et al reported that 3w chronic stress decreased 5-HT and DA levels
in whole brain, without effects on NE or 5-HIAA (19). This incon-
sistence may be associated with variable experimental procedures,e.g., different stressors, sequence, intensity, duration, and so on. In
fact, depression patients are proposed to show two types of char-
acteristics, ‘noradrenergic’ depression or ‘serotonergic’ depression.
Under our experimental condition, changes in NE system, but not 5-
HT or DA, were involved in neurochemical endpoints in CUS model
and antidepressant effects of 071031B. However, we must bear in
mind that, in this study, we did not determine monoamine levels in
hippocampus or other areas; therefore, we can not rule out the
possibility of a brain-region speciﬁc effect.
5. Conclusion
Our study demonstrates that 071031B produces potent inhibi-
tion of 5-HT and NE uptake in vivo. Moreover, this study supports
and extends our previous studies, and suggests that 071031B may
be an effective antidepressant requiring clinical evaluation.
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